ACVR2A and plasma cell myeloma: In contrast to BMPR1a-FC, we found an activin ligand trap (ACVR2a-FC) to slightly increase osteoclastogenesis (Fig. 4f, g), demonstrating that BMP and activin inhibition have non-equivalent effects on myeloma bone disease in this model system.